Mild cognitive impairment: New neuropsychological and pharmacological target

Rafael A. Rivas-Vazquez, Cecilia Mendez, Gustavo Rey, Enrique J. Carrazana

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Mild cognitive impairment (MCI) is increasingly being conceptualized in the literature as a cognitive disturbance representing a transitional phase between normal aging and dementia. The operational definitions of MCI provide an opportunity for neuropsychologists to detect subtle deficit and monitor cognitive status sequentially in order to determine rate and degree of progression. More importantly, clinical and neuropsychological studies are needed that can better characterize which MCI patients are at greatest risk for conversion to dementia. Preliminary data has also designated MCI as a potential indicator for initiation of pharmacotherapy, with the objective of decelerating rate of progression to dementia. Current criteria and clinical issues related to MCI are discussed, with the objective of better familiarizing clinicians with this syndrome and fostering ongoing investigations.

Original languageEnglish (US)
Pages (from-to)11-27
Number of pages17
JournalArchives of Clinical Neuropsychology
Volume19
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Pharmacology
Dementia
Foster Home Care
Cognitive Dysfunction
Drug Therapy

Keywords

  • Alzheimer's disease
  • Mild cognitive impairment
  • Prodromal Alzheimer's disease

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Neuropsychology and Physiological Psychology

Cite this

Mild cognitive impairment : New neuropsychological and pharmacological target. / Rivas-Vazquez, Rafael A.; Mendez, Cecilia; Rey, Gustavo; Carrazana, Enrique J.

In: Archives of Clinical Neuropsychology, Vol. 19, No. 1, 01.2004, p. 11-27.

Research output: Contribution to journalArticle

Rivas-Vazquez, Rafael A. ; Mendez, Cecilia ; Rey, Gustavo ; Carrazana, Enrique J. / Mild cognitive impairment : New neuropsychological and pharmacological target. In: Archives of Clinical Neuropsychology. 2004 ; Vol. 19, No. 1. pp. 11-27.
@article{6c683f3dce6546cdaed106e52597b0de,
title = "Mild cognitive impairment: New neuropsychological and pharmacological target",
abstract = "Mild cognitive impairment (MCI) is increasingly being conceptualized in the literature as a cognitive disturbance representing a transitional phase between normal aging and dementia. The operational definitions of MCI provide an opportunity for neuropsychologists to detect subtle deficit and monitor cognitive status sequentially in order to determine rate and degree of progression. More importantly, clinical and neuropsychological studies are needed that can better characterize which MCI patients are at greatest risk for conversion to dementia. Preliminary data has also designated MCI as a potential indicator for initiation of pharmacotherapy, with the objective of decelerating rate of progression to dementia. Current criteria and clinical issues related to MCI are discussed, with the objective of better familiarizing clinicians with this syndrome and fostering ongoing investigations.",
keywords = "Alzheimer's disease, Mild cognitive impairment, Prodromal Alzheimer's disease",
author = "Rivas-Vazquez, {Rafael A.} and Cecilia Mendez and Gustavo Rey and Carrazana, {Enrique J.}",
year = "2004",
month = "1",
doi = "10.1016/S0887-6177(02)00167-1",
language = "English (US)",
volume = "19",
pages = "11--27",
journal = "Archives of Clinical Neuropsychology",
issn = "0887-6177",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Mild cognitive impairment

T2 - New neuropsychological and pharmacological target

AU - Rivas-Vazquez, Rafael A.

AU - Mendez, Cecilia

AU - Rey, Gustavo

AU - Carrazana, Enrique J.

PY - 2004/1

Y1 - 2004/1

N2 - Mild cognitive impairment (MCI) is increasingly being conceptualized in the literature as a cognitive disturbance representing a transitional phase between normal aging and dementia. The operational definitions of MCI provide an opportunity for neuropsychologists to detect subtle deficit and monitor cognitive status sequentially in order to determine rate and degree of progression. More importantly, clinical and neuropsychological studies are needed that can better characterize which MCI patients are at greatest risk for conversion to dementia. Preliminary data has also designated MCI as a potential indicator for initiation of pharmacotherapy, with the objective of decelerating rate of progression to dementia. Current criteria and clinical issues related to MCI are discussed, with the objective of better familiarizing clinicians with this syndrome and fostering ongoing investigations.

AB - Mild cognitive impairment (MCI) is increasingly being conceptualized in the literature as a cognitive disturbance representing a transitional phase between normal aging and dementia. The operational definitions of MCI provide an opportunity for neuropsychologists to detect subtle deficit and monitor cognitive status sequentially in order to determine rate and degree of progression. More importantly, clinical and neuropsychological studies are needed that can better characterize which MCI patients are at greatest risk for conversion to dementia. Preliminary data has also designated MCI as a potential indicator for initiation of pharmacotherapy, with the objective of decelerating rate of progression to dementia. Current criteria and clinical issues related to MCI are discussed, with the objective of better familiarizing clinicians with this syndrome and fostering ongoing investigations.

KW - Alzheimer's disease

KW - Mild cognitive impairment

KW - Prodromal Alzheimer's disease

UR - http://www.scopus.com/inward/record.url?scp=0344256425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344256425&partnerID=8YFLogxK

U2 - 10.1016/S0887-6177(02)00167-1

DO - 10.1016/S0887-6177(02)00167-1

M3 - Article

C2 - 14670376

AN - SCOPUS:0344256425

VL - 19

SP - 11

EP - 27

JO - Archives of Clinical Neuropsychology

JF - Archives of Clinical Neuropsychology

SN - 0887-6177

IS - 1

ER -